iSpecimen Inc.

ISPC ·Healthcare, Diagnostics & Research, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-10.5M $-12.5M $-11.1M $-10.2M $-9.0M $-4.7M
Depreciation & Amortization $1.7M $2.3M $2.1M — — —
Depreciation $68.5K $65.7K $117.5K $22.4K $45.4K $44.8K
Amortization $191.6K $191.6K $49.5K $1.2M $958.6K $774.9K
Stock-Based Compensation $21.3K $249.7K $459.7K $678.6K $622.1K $92.9K
Net Cash from Operating Activities $-4.2M $-8.3M $-5.8M $-5.8M $-10.7M $-288.4K
Investing Activities
Capital Expenditures $454 $31.5K $19.5K $215.5K $2.6K $426
Business Acquisitions — — — — — —
Net Cash from Investing Activities $-1.0M $2.0M $-7.2M $-3.2M $-1.0M $-1.1M
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — — — —
Net Cash from Financing Activities $10.2M $5.8M $70.9K $-3.4M $38.7M $2.0M
Net Change in Cash — — — — — —
Free Cash Flow $-4.2M $-8.3M $-5.8M $-6.0M $-10.7M $-288.8K